ReviewProbiotics and antimicrobial proteins2025
The Synergistic and Chimeric Mechanism of Bacteriophage Endolysins: Opportunities for Application in Biotherapeutics, Food, and Health Sectors.
Review in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A dual-functional dendrimer-based system integrating recombinant endolysin and cinnamic acid for enhanced endolysin stability and antibacterial activity against Acinetobacter baumannii.World journal of microbiology & biotechnology · 2026Article
- Antimicrobial Peptide Fusion and Alginate Encapsulation Broaden the Antibacterial Spectrum and Preserve Storage Stability of the EndolysinACS omega · 2026Article
- Characterisation of a NovelPathogens (Basel, Switzerland) · 2025Article
- Investigating the novel Escherichia coli bacteriophage Jgk1 as a potential antimicrobial agent.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Integrative In Silico and Experimental Characterization of Endolysin LysPALS22: Structural Diversity, Ligand Binding Affinity, and Heterologous Expression.International journal of molecular sciences · 2025Article
- [Phage endolysins-a novel class of antibacterial agents with a wide range of applications].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Review
- [Application of phages in farm animals, food and the environment as part of a One Health approach-potentials and challenges].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Article
- The impact of metagenomic analysis on the discovery of novel endolysins.Applied microbiology and biotechnology · 2025Review
- Harnessing the Activity of Lytic Bacteriophages to Foster the Sustainable Development Goals and the "One Health" Strategy.Viruses · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major growing concern in the human and animal health sector is the emergence of antibiotic-resistant pathogenic bacteria due to the indiscriminate use of antibiotics. The exogenous application of bacteriophage endolysins causes abrupt lysis of the bacterial cell wall, which computes them as alternatives to antibiotics. Although naturally occurring endolysins may display limitations in solubility, lytic activity, and narrow lytic spectrum, novel strategies like developing chimeric endolysins and using endolysins in synergism with other antimicrobial agents are required to improve the lytic activity of natural endolysins. The modular structure of endolysins led to the development of novel chimeric endolysins via shuffling enzymatic and cell wall binding domains of different endolysins, using endolysins in a synergistic approach, and their applications in various in vitro and in vivo experiments and different applicable areas. This article aims to review the role of chimeric endolysins and their use in synergistic mode with other biofilm-reducing agents to control biofilm formation and deteriorating pre-formed biofilms in food, dairy, and medical industries. Promoting further development of phage technology and innovation in antibiotic therapy can achieve long-term sustainable development and economic returns.
Indexed as
Identifiers
39508962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.